Mizuho analyst Mara Goldstein initiated coverage of Immuneering with a Neutral rating and $10 price target. The shares have doubled year-to-date following news that interim Phase I dose escalation IMM-1-104 data will be available in Q2, but clinical evidence of feasibility is now needed to expand the valuation further, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMRX:
- Immuneering appoints Harold Brakewood as CBO
- Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates
- Immuneering presents preclinical data with lead program IMM-1-104
- Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity